Drugs / IO102-IO103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05155254 | May 2022 → May 2025 overdue | metastatic melanoma | IO Biotech | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | IO Biotech | Results IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications iobiotech.com ↗
The MM1636 results published today showed the five-year follow-up analysis of IO102-IO103 in combination with nivolumab in patients with metastatic melanoma, demonstrating durable clinical activity with a 25.5-month median progression-free survival (PFS). |
| 2025-10-20 | IO Biotech | Results IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 iobiotech.com ↗
Despite the narrow miss on statistical significance, I am encouraged by the clinically meaningful improvement in progression-free survival observed with IO102-IO103 plus pembrolizumab. |
| 2025-09-29 | IO Biotech | Regulatory IO Biotech Provides Update Following Pre-BLA Meeting with FDA iobiotech.com ↗
The FDA has recommended that IO Biotech not submit a BLA based on the data from the IOB-013 clinical trial. |
| 2025-04-25 | IO Biotech | Results IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 iobiotech.com ↗
IO102-IO103, a dual-antigen vaccine targeting IDO1+ and PD-L1+ cells, generated strong T-cell responses and modulated the tumor microenvironment in two mouse models, where IDO1 and PD-L1 vaccine each contributed differently to control tumor growth. |
| 2024-11-07 | IO Biotech | Results IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study iobiotech.com ↗
Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached |
| 2024-09-14 | IO Biotech | Results IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer iobiotech.com ↗
The data from 18 efficacy evaluable patients demonstrated: Achievement of the primary endpoint – confirmed 44.4% overall response rate (ORR) in a PD-L1 high population of patients with SCCHN irrespective of HPV status. |
| 2024-08-30 | IO Biotech | Results IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma iobiotech.com ↗
Based on their review of the safety and efficacy data, the IDMC recommended that the trial continue without modifications and noted that no new safety signals were observed. |
| 2024-04-09 | IO Biotech | Results IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 iobiotech.com ↗ |
| 2024-03-06 | IO Biotech | Results IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting iobiotech.com ↗
These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively. |
| 2023-11-01 | IO Biotech | Results IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting iobiotech.com ↗
The data in this poster demonstrate enhanced in vivo anti-tumor effect when IDO and PD-L1 vaccines are co-administered in these models, further supporting the clinical observations regarding our lead investigational therapeutic vaccine candidate, IO102-IO103, which targets IDO and PD-L1. |
| 2023-10-23 | IO Biotech | Results Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress iobiotech.com ↗ |
| 2023-09-12 | IO Biotech | Results IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer iobiotech.com ↗
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer |
| 2023-01-09 | IO Biotech | Results IO Biotech Provides Business Update iobiotech.com ↗
Encouraging initial data reported from 9 evaluable non-small cell lung cancer patients from the company’s ongoing Phase 2 solid tumor basket trial evaluating IO102-IO103 in combination with pembrolizumab; the company anticipates additional data from this study in 2023. |
| 2022-11-09 | IO Biotech | Results IO Biotech Announces Third Quarter Results for 2022 iobiotech.com ↗
Results from a new October 2022 data cut for the MM1636 Phase 1/2 study with IO102-IO103 in combination with nivolumab for metastatic melanoma continue to be encouraging with median overall survival (mOS) at 46.8 months; median progression free survival (mPFS) at 22.5 months, and a complete response rate of 50% |
| 2022-04-08 | IO Biotech | Results IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting iobiotech.com ↗ |
| 2021-12-09 | IO Biotech | Results IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine iobiotech.com ↗
today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial in Nature Medicine that can be found HERE. |
| 2020-12-15 | IO Biotech | Regulatory The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma iobiotech.com ↗
Copenhagen, Denmark – December 15, 2020: IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. |
All press releases naming this drug 23 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO102-IO103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155254 ↗ |
| Modality | Peptide | “IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103)” NCT05155254 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05155254 ↗ |